Browsing publications by Kevin Fishwick

Newcastle AuthorsTitleYearFull text
Dr Ashraf Azzabi
Dr Andrew Hughes
Dr Paula Calvert
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations2005
Dr Mark Verrill
Professor Alan Boddy
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors2003
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study2002
Dr Andrew Hughes
Dr Paula Calvert
Dr Ashraf Azzabi
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma2002
Kevin Fishwick
The EORTC Clinical Research Coordinators Group2002
Dr Andrew Simpson
Dr Paula Calvert
Julieann Sludden
Professor Alan Boddy
Melanie Griffin
et al.
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules2002
Dr Andrew Hughes
Dr Ashraf Azzabi
Professor Ruth Plummer
Dr Jane Margetts
Kevin Fishwick
et al.
A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate).2001
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer2001
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Kevin Fishwick
et al.
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate2001
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer2000
12